Abstract: The present invention relates to a composition for improving memory, improving cognition, preventing or treating cerebral neurological disease, comprising porcine brain enzyme hydrolysate. The composition can exhibit neuroprotective activity, brain-derived neurotrophic factor (BDNF) production activity, acetylcholinesterase inhibitory activity and reactive oxygen species (ROS) inhibitory activity.

Abstract: A power module includes at least one semiconductor chip, at least one substrate that supports the at least one semiconductor chip, and a first lead. The first lead includes (i) an extended portion having a first end connected to the at least one substrate and a second end protruding outward away from the at least one substrate and (ii) a resistance portion disposed between the first end and the second end of the extended portion.

Abstract: An object of the present invention is to provide a material for organic EL elements, the material being excellent in hole injecting/transporting performance, electron-blocking capability, stability in the form of a thin film, and durability. Another object of the present invention is to provide an organic EL element having high efficiency, a low driving voltage, and a long lifespan, by combining the aforementioned material with various materials for organic EL elements, the materials being excellent in hole/electron injecting/transporting performance, electron-blocking capability, stability in the form of a thin film, and durability, such that the properties of the individual materials can be effectively exhibited.

Abstract: A virtual machine provisioning method according to an embodiment includes a provisioning module that creates a virtual machine image template including only an operating system image and a system file image, a virtual machine management module that extracts the OS image of the virtual machine image template according to a virtual machine creation command from a user, to load the OS image into a memory allocated a virtual machine, and execute the OS image, and an interface module that extracts a system file image of the virtual machine image template according to the virtual machine creation command to build a root file system for the virtual machine.

Abstract: A virtual machine provisioning method according to an embodiment includes a provisioning module that creates a virtual machine image template including only an operating system image and a system file image, a virtual machine management module that extracts the OS image of the virtual machine image template according to a virtual machine creation command from a user, to load the OS image into a memory allocated a virtual machine, and execute the OS image, and an interface module that extracts a system file image of the virtual machine image template according to the virtual machine creation command to build a root file system for the virtual machine.

Abstract: The present invention relates to a pharmaceutical composition containing a G protein coupled receptor 119 (GPR119) ligand as an effective ingredient for preventing or treating non-alcoholic steatohepatitis. More particularly, it was confirmed that the GPR119 ligand, which has been developed as only an anti-diabetic drug, exhibits superior effects on the treatment of non-alcoholic fatty liver and the signal pathways in hepatocytes therefor differ from the signal pathways in the small intestine and the pancreas exhibiting anti-diabetic effects, whereby the GPR119 ligand can be useful to treat non-alcoholic steatohepatitis.

Abstract: Provided is a pharmaceutical composition for preventing or treating liver fibrosis, comprising a GPR119 ligand as an active ingredient. The composition comprising the GPR119 ligand as an active ingredient significantly inhibits the expression of collagen I, transforming growth factor ? (TGF?) and ?-smooth muscle actin (?-SMA), thereby inhibiting HSC activation, and also significantly inhibits HSC proliferation. Therefore, the composition may be effectively applied in improvement, prevention, inhibition or treatment of liver fibrosis.

Abstract: Provided is a pharmaceutical composition for preventing or treating liver fibrosis, comprising a GPR119 ligand as an active ingredient. The composition comprising the GPR119 ligand as an active ingredient significantly inhibits the expression of collagen I, transforming growth factor ? (TGF?) and ?-smooth muscle actin (?-SMA), thereby inhibiting HSC activation, and also significantly inhibits HSC proliferation.

Abstract: The present invention relates to a pharmaceutical composition containing a G protein coupled receptor 119 (GPR119) ligand as an active ingredient for preventing or treating non-alcoholic fatty liver disease. More particularly, it was confirmed that the GPR119 ligand, which has been developed as only an anti-diabetic drug, exhibits superior effects on the treatment of non-alcoholic fatty liver and the signal pathways in hepatocytes therefor differ from the signal pathways in the small intestine and the pancreas exhibiting anti-diabetic effects, whereby the GPR119 ligand can be useful to treat non-alcoholic fatty liver.